Cancer vaccine - Bioimmulance

Drug Profile

Cancer vaccine - Bioimmulance

Alternative Names: MAGE-A4/Survivin cancer vaccine; Survivin/MAGE-A4 cancer vaccine

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Bioimmulance
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(Second-line therapy or greater, Treatment-experienced) in Japan (Intratumoural, Injection)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(Second-line therapy or greater, Treatment-experienced) in Japan (SC, Injection)
  • 07 Sep 2011 Phase-I clinical trials in Cancer in Japan (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top